Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05OZQ
|
|||
| Drug Name |
Efpeglenatide
|
|||
| Synonyms |
Langlenatide; Efpeglenatide [INN]; Langlenatide [WHO-DD]; UNII-3M1V5Z2270; SCHEMBL19712179; 3M1V5Z2270; 1296200-77-5
Click to Show/Hide
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11] | Phase 3 | [1] | |
| Company |
Sanofi US Bridgewater, NJ
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H37N3O6
|
|||
| Canonical SMILES |
C1CC(N(C1)CCCOCCOCCCNCCCCC(C(=O)O)N)C(=O)O
|
|||
| InChI |
1S/C19H37N3O6/c20-16(18(23)24)6-1-2-8-21-9-4-12-27-14-15-28-13-5-11-22-10-3-7-17(22)19(25)26/h16-17,21H,1-15,20H2,(H,23,24)(H,25,26)/t16-,17-/m0/s1
|
|||
| InChIKey |
OJQLGILETRTDGQ-IRXDYDNUSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Agonist | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Insulin secretion | ||||
| Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
| G alpha (s) signalling events | ||||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03496298) Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.